Hansa Biopharma (HNSA) investor relations material

Executive summary

• Q1 2026 was a transition period marked by significant organizational restructuring, leadership changes, and system upgrades, with a focus on capital efficiency and execution against strategic priorities.

• Revenue for Q1 2026 was SEK 34.6 million, down 48% year-over-year from SEK 66.3 million, mainly due to European restructuring and organ allocation dynamics.

• Financial runway was extended through a $30 million convertible note, deferred debt payments, and strengthened balance sheet.

• Regulatory progress included FDA acceptance of imlifidase BLA, assignment of a PDUFA date for December 19, 2026, and briefing package submission for GBS.

• Key clinical milestones expected in 2026 include PAES and ConfIdeS data readouts, FDA feedback on GBS, and a planned EMA filing for full approval of Idefirix.

Financial highlights

• Q1 2026 total revenue: SEK 34.6 million, with product sales of SEK 33.9 million, both down 48% year-over-year.

• SG&A expenses: SEK 106 million, up year-over-year due to LTIP, convertible note fees, U.S. launch investments, and a one-off 10 MSEK financing cost.

• R&D expenses: SEK 57 million, down from Q1 2025 due to clinical trial wind-down and restructuring.

• Loss from operations: SEK 143 million, compared to SEK 93–125 million in prior periods.

• Cash and cash equivalents at quarter-end: SEK 677 million.

Outlook and guidance

• Management expects growth in the second half of 2026, driven by new data releases, commercial initiatives, and U.S. launch preparations.

• Early Q2 trends show improved sales in multiple European markets.

• Key upcoming events: PAES study database lock, ConfIdeS Phase 3 data at ATC, EMA filing for full approval, and Capital Markets Day in June.